These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1607032)

  • 1. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival.
    Locker AP; Birrell K; Bell JA; Nicholson RI; Elston CW; Blamey RW; Ellis IO
    Eur J Surg Oncol; 1992 Jun; 18(3):224-9. PubMed ID: 1607032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the cell cycle-associated monoclonal antibody Ki-S1 as a prognostic factor in primary invasive adenocarcinoma of the breast.
    Morris ES; Elston CW; Bell JA; Galea M; Blamey RW; Ellis IO
    J Pathol; 1995 May; 176(1):55-62. PubMed ID: 7616357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables.
    Barnard NJ; Hall PA; Lemoine NR; Kadar N
    J Pathol; 1987 Aug; 152(4):287-95. PubMed ID: 3668731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis.
    Li SS; Xue WC; Khoo US; Ngan HY; Chan KY; Tam IY; Chiu PM; Ip PP; Tam KF; Cheung AN
    Histopathology; 2005 Mar; 46(3):307-13. PubMed ID: 15720416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer.
    Aaltomaa S; Lipponen P; Syrjänen K
    Anticancer Res; 1993; 13(2):533-8. PubMed ID: 8100128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
    Siitonen SM; Kallioniemi OP; Isola JJ
    Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
    Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
    Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
    Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of nuclear morphometric variables as prognostic predictors in breast cancer.
    Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
    Anticancer Res; 1991; 11(4):1663-9. PubMed ID: 1746922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma.
    Sampson SA; Kreipe H; Gillett CE; Smith P; Chaudary MA; Khan A; Wicks K; Parwaresch R; Barnes DM
    J Pathol; 1992 Oct; 168(2):179-85. PubMed ID: 1460535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
    Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
    Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
    Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the growth fraction, nucleolar organizer region counts and epidermal growth factor receptor with histomorphological prognostic criteria in breast cancer.
    Gupta GR; Datta BN; Bose SM; Joshi K
    Indian J Pathol Microbiol; 1997 Jan; 40(1):3-10. PubMed ID: 9145604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.